Zimmer, Benvenue Medical conclude distribution deal

Zimmer Spine has concluded a deal through which it will distribute Benvenue Medical's Kiva VCF treatment system. The system, which has CE Mark approval, is used to treat vertebral compression fractures.

The system will initially be distributed in Germany and Italy and will reach a broader audience throughout the EU shortly. The minimally invasive VCF market in the EU was estimated to be $185 million in 2010, according to a statement. 

"The Kiva System represents Zimmer Spine's first VCF product offering for our customers. This differentiated VCF system is a natural extension to our existing product lines," explains Hubert Piatkowski, VP, Zimmer Spine, in a statement.

Kiva is being evaluated against balloon kyphoplasty in VCFs in the KAST study at three sites in Europe. KAST is the largest randomized study versus balloon kyphoplasty to date and is being conducted in support of a future 510(k) market clearance in the U.S. Earlier this year, Benvenue snagged $35.5 milllion in a Series C financing round to continue the study.

- check out the Zimmer/Benvenue Medical release

Special Report: Benvenue Medical - Top 10 medical device VC deals, H1 2011

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.